Hiệu quả và tính an toàn điều trị bước một u thần kinh nội tiết tiến triển, di căn không thể phẫu thuật tại khoa nội tuyến vú, tiêu hóa, gan, niệu - Bệnh viện Ung Bướu TP. Hồ Chí Minh=Effectiveness and safety of first-line treatment of advanced neuroendocrine neoplasms treatment at the department of breast, gastroenterology, hepatology, and urology

Hiệu quả và tính an toàn điều trị bước một u thần kinh nội tiết tiến triển, di căn không thể phẫu thuật tại khoa nội tuyến vú, tiêu hóa, gan, niệu - Bệnh viện Ung Bướu TP. Hồ Chí Minh=Effectiveness and safety of first-line treatment of advanced neuroendocrine neoplasms treatment at the department of breast, gastroenterology, hepatology, and urology – Ho Chi Minh City Oncology Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hoàng Quý Nguyễn, Như Thành Nguyễn, Thị Hồng Đức Phan

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.466-473

Bộ sưu tập: Metadata

ID: 245868

Thêm vào giỏ

Đánh giá thời gian sống còn không bệnh tiến triển (PFS), tỉ lệ đáp ứng (ORR), tỉ lệ kiểm soát bệnh (DCR), phân tích một số yếu tổ ảnh hưởng sống còn và tác dụng phụ điều trị bước một trên hai nhóm bệnh nhân: nhóm A - các khối u thần kinh nội tiết biệt hóa (NETs) và nhóm B – các ung thư biểu mô thần kinh nội tiết (NECs). Đối tượng và phương pháp: Nghiên cứu mô tả hồi cứu cắt ngang trên 35 bệnh nhân u thần kinh nội tiết tiến triển, di căn tại khoa Nội tuyến vú, tiêu hóa, gan, niệu – BV Ung Bướu TP. HCM. Kết quả: Nhóm A (20 bệnh nhân NETs): tỉ lệ đáp ứng và tỉ lệ kiểm soát bệnh điều trị bước một với octreotide lần lượt là 20% và 70%
trung vị thời gian sống còn không bệnh tiến triển (mPFS) là 18,9 tháng. Nhóm B (15 bệnh nhân NECs): tỉ lệ đáp ứng và tỉ lệ kiểm soát bệnh điều trị bước một với phác đồ hóa trị etoposide-cisplatin (EP) lần lượt là 26,7% và 60%
trung vị thời gian sống còn không bệnh tiến triển là 5,0 tháng. Độc tính xảy ra chủ yếu trên nhóm bệnh nhân NECs được hóa trị với các tác dụng phụ thường gặp: thiếu máu (52,9%), giảm bạch cầu hạt (38,8%), nôn ói (43,4%), mệt mỏi (45,2%). Kết luận: Điều trị toàn thân các u thần kinh nội tiết biệt hóa NETs với octreotide giúp kéo dài thời gian sống còn không bệnh tiến triển với độc tính không đáng kể. Đối với các trường hợp NECs bệnh diễn tiến nhanh, mặc dù có đáp ứng ban đầu với hóa trị nhưng bệnh tiếp tục tiến triển sau đó.Evaluate progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), analysis of factors affecting progression-free survival adverse effects of first-line treatment in two groups of patients: group A - differentiated neuroendocrine tumors (NETs) and group B - neuroendocrine carcinomas (NECs). Materials and methods: A retrospective cross-sectional descriptive study 35 patients with advanced, metastatic neuroendocrine tumors at the department of breast, gastroenterology, hepatology, and urology – Hochiminh City Oncology hospital. Results: Group A (25 NETs patients): Response rate and disease control rate of firstline treatment with octreotide were 20% and 70%, respectively
median progression-free survival (mPFS) was 18.9 months. Group B (15 NECs patients): response rate and disease control rate of first-line treatment with etoposidecisplatin (EP) chemotherapy regimen were 26.7% and 60%, respectively
median progression-free survival was 5.0 months. Toxicity occurs mainly in the group of NECs patients receiving chemotherapy with common side effects: anemia (52.9%), neutropenia (38.8%), vomiting (43.4%) , fatigue (45.2%). Conclusion: Systemic treatment of differentiated neuroendocrine tumors NETs with octreotide prolongs progression-free survival with negligible toxicity. In cases of NECs, the disease progresses rapidly, although there is an initial response to chemotherapy, the disease continues to progress afterward.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR